A multi-centre 3-year follow-up study to assess the viral activity in patients who failed to achieve sustained virologic response in Novartis-sponsored alisporivir studies for chronic hepatitis C patients

Trial Profile

A multi-centre 3-year follow-up study to assess the viral activity in patients who failed to achieve sustained virologic response in Novartis-sponsored alisporivir studies for chronic hepatitis C patients

Discontinued
Phase of Trial: Phase III

Latest Information Update: 15 Jan 2018

At a glance

  • Drugs Alisporivir (Primary)
  • Indications Hepatitis C
  • Focus Pharmacodynamics
  • Sponsors Novartis Pharma A.G.
  • Most Recent Events

    • 13 Dec 2017 Status changed from completed to discontinued.
    • 10 Jun 2017 Biomarkers information updated
    • 19 Dec 2012 Integrated Clinical Trials Registry - India record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top